Abstract
Mesothelin (MSLN) is a cell surface protein associated with tumor invasion and metastasis. This study aims to explore the biological function of MSLN in gastric cancer and to evaluate the association of MSLN polymorphism (rs3764247, rs3764246, rs12597489, rs1057147, rs3765319) with the risk and prognosis of gastric cancer. Small interfering RNA (siRNA) transfection and MSLN overexpression were performed in human gastric cancer cell lines, respectively. The proliferation of tumor cells was evaluated by Cell counting kit 8(CCK-8) and colony formation assay. Wound healing assay and transwell assay were used to elucidate gastric cancer cell migration and invasion rates. We conducted a case–control study involving 860 patients with gastric cancer and 870 controls. All mutation sites were genotyped by PCR-LDR sequencing. First, our study revealed the cancer-promoting role of MSLN in gastric cancer. Second, we also demonstrated that rs3764247 and rs3764246 were associated with a reduced risk of gastric cancer (OR = 0.83, p = 0.010; OR = 0.84, p = 0.011; respectively). The clinicopathological analysis further showed that rs3764247 was closely related to T stage, vascular infiltration, and HER2 expression. In addition, in the survival analysis of 392 patients with gastric cancer, patients with rs3764247 CC genotype had poorer survival than patients with AA + AC genotype after adjusting for age, sex, TNM stage, and Lauren classification (HR = 2.07, p = 0.029). Our findings indicated that MSLN could be an oncogene whose polymorphisms were closely related to the risk and prognosis of gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- TCGA:
-
The Cancer Genome Atlas
- GEO:
-
Gene Expression Omnibus
- GTEX:
-
Genotype-Tissue Expression
- SNP:
-
Single nucleotide polymorphism
- MAF:
-
Minor allele frequencies
- HWE:
-
Hardy–Weinberg equilibrium
- GWAS:
-
Genome-wide association study
- OR:
-
Odds ratio
- HR:
-
Hazard ratio
- CI:
-
Confidence interval
- DHS:
-
DNase I hypersensitive site
- HPA:
-
Human protein atlas
- UCSC:
-
University of California Santa Cruz
References
Abou-El-Naga AM, Abo El-Khair SM, Mahmoud AZ, Hamza M, Elshazli RM (2021) Association of genetic variants in the 3’-untranslated region of the mesothelin (MSLN) gene with ovarian carcinoma. J Biochem Mol Toxicol 35(2):e22637. https://doi.org/10.1002/jbt.22637
Baba K, Ishigami S, Arigami T et al (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105(2):195–199. https://doi.org/10.1002/jso.22024
Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20(8):2902–2906. https://doi.org/10.1128/MCB.20.8.2902-2906.2000
Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011) Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32(7):1013–1024. https://doi.org/10.1093/carcin/bgr075
Brown LM, Devesa SS (2002) Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 11(2):235–256. https://doi.org/10.1016/s1055-3207(02)00002-9
Chang MC, Chen CA, Chen PJ et al (2012) Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J 442(2):293–302. https://doi.org/10.1042/BJ20110282
Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K (2013) Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 3:1870. https://doi.org/10.1038/srep01870
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338
Coelho R, Ricardo S, Amaral AL et al (2020) Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis 9(6):61. https://doi.org/10.1038/s41389-020-00246-2
Duan F, Song C, Shi J et al (2021) Identification and epidemiological evaluation of gastric cancer risk factors: based on a field synopsis and meta-analysis in Chinese population. Aging (albany NY) 13(17):21451–21469. https://doi.org/10.18632/aging.203484
Einama T, Homma S, Kamachi H et al (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107(1):137–142. https://doi.org/10.1038/bjc.2012.235
Fagny M, Platig J, Kuijjer ML, Lin X, Quackenbush J (2020) Nongenic cancer-risk SNPs affect oncogenes, tumour-suppressor genes, and immune function. Br J Cancer 122(4):569–577. https://doi.org/10.1038/s41416-019-0614-3
Frierson HF Jr, Moskaluk CA, Powell SM et al (2003) Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34(6):605–609. https://doi.org/10.1016/s0046-8177(03)00177-1
Garieri M, Delaneau O, Santoni F et al (2017) The effect of genetic variation on promoter usage and enhancer activity. Nat Commun 8(1):1358. https://doi.org/10.1038/s41467-017-01467-7
Guo H, Yang J, Liu S et al (2021) Prognostic marker identification based on weighted gene co-expression network analysis and associated in vitro confirmation in gastric cancer. Bioengineered 12(1):4666–4680. https://doi.org/10.1080/21655979.2021.1957645
Heinz S, Romanoski CE, Benner C et al (2013) Effect of natural genetic variation on enhancer selection and function. Nature 503(7477):487–492. https://doi.org/10.1038/nature12615
Hirakawa H, Shirasawa K, Ohyama A et al (2013) Genome-wide SNP genotyping to infer the effects on gene functions in tomato. DNA Res 20(3):221–233. https://doi.org/10.1093/dnares/dst005
Hu Y, Huang C, Sun Y et al (2016) Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 34(12):1350–1357. https://doi.org/10.1200/JCO.2015.63.7215
Ito T, Kajino K, Abe M et al (2014) ERC/mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol Rep 31(1):27–33. https://doi.org/10.3892/or.2013.2803
Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer 3:137–144. https://doi.org/10.7150/jca.4090
Kachala SS, Bograd AJ, Villena-Vargas J et al (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20(4):1020–1028. https://doi.org/10.1158/1078-0432.CCR-13-1862
Ke X, Taylor MS, Cardon LR (2008) Singleton SNPs in the human genome and implications for genome-wide association studies. Eur J Hum Genet 16(4):506–515. https://doi.org/10.1038/sj.ejhg.5201987
Kendrick ZW, Firpo MA, Repko RC et al (2014) Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (oxford) 16(7):670–676. https://doi.org/10.1111/hpb.12199
Klampatsa A, Dimou V, Albelda SM (2021) Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther 21(4):473–486. https://doi.org/10.1080/14712598.2021.1843628
Le K, Wang J, Zhang T et al (2020) Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci 17(4):422–427. https://doi.org/10.7150/ijms.39012
Liang B, Ding H, Huang L, Luo H, Zhu X (2020) GWAS in cancer: progress and challenges. Mol Genet Genomics 295(3):537–561. https://doi.org/10.1007/s00438-020-01647-z
Lin L, Xiao J, Shi L et al (2019) STRA6 exerts oncogenic role in gastric tumorigenesis by acting as a crucial target of miR-873. J Exp Clin Cancer Res 38(1):452. https://doi.org/10.1186/s13046-019-1450-2
Lyons K, Le LC, Pham YT et al (2019) Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev 28(5):397–412. https://doi.org/10.1097/CEJ.0000000000000480
Mattioli K, Volders PJ, Gerhardinger C et al (2019) High-throughput functional analysis of lncRNA core promoters elucidates rules governing tissue specificity. Genome Res 29(3):344–355. https://doi.org/10.1101/gr.242222.118
Melaiu O, Stebbing J, Lombardo Y et al (2014) MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS ONE 9(1):e85935. https://doi.org/10.1371/journal.pone.0085935
Melaiu O, Stebbing J, Lombardo Y et al (2017) Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS ONE 12(6):e0180317. https://doi.org/10.1371/journal.pone.0180317
Milne AN, Carvalho R, Morsink FM et al (2006) Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 19(4):564–572. https://doi.org/10.1038/modpathol.3800563
Praud D, Rota M, Pelucchi C et al (2018) Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. Eur J Cancer Prev 27(2):124–133. https://doi.org/10.1097/CEJ.0000000000000290
Servais EL, Colovos C, Rodriguez L et al (2012) Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 18(9):2478–2489. https://doi.org/10.1158/1078-0432.CCR-11-2614
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Takihata Y, Einama T, Kobayashi K et al (2021) Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma. Oncol Lett 21(5):414. https://doi.org/10.3892/ol.2021.12675
Wang Y, Wang L, Li D, Wang HB, Chen QF (2012) Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res 40(6):2109–2116. https://doi.org/10.1177/030006051204000608
Weidemann S, Gagelmann P, Gorbokon N et al (2021) Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines. https://doi.org/10.3390/biomedicines9040397
Wu MS, Chen CJ, Lin JT (2005) Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 14(8):1878–1882. https://doi.org/10.1158/1055-9965.EPI-04-0792
Xiao J, Zhu C, Ni P et al (2021) Correlations of SNHG5 genetic polymorphisms with susceptibility and prognosis to gastric cancer in a Chinese population. Genomics 113(4):1754–1760. https://doi.org/10.1016/j.ygeno.2021.04.025
Zeng H, Chen W, Zheng R et al (2018) Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 6(5):e555–e567. https://doi.org/10.1016/S2214-109X(18)30127-X
Zhang XY, Zhang PY (2017) Gastric cancer: somatic genetics as a guide to therapy. J Med Genet 54(5):305–312. https://doi.org/10.1136/jmedgenet-2016-104171
Funding
This study was financially supported by Special Foundation for National Science and Technology Basic Research Program of China (2019FY101104); the National Nature Science Foundation of China (81874219).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shen, K., Liu, K., Wang, Y. et al. Polymorphisms of an oncogenic gene, mesothelin, predict the risk and prognosis of gastric cancer in a Chinese Han population. Arch Toxicol 96, 2097–2111 (2022). https://doi.org/10.1007/s00204-022-03290-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-022-03290-6